tpan.com Quick Links

2004 HIV Drug Guide

2004 HIV Services Directory

Positively Aware

Positively Aware en Español

We need your input! Please take a few moments to participate in the Positively Aware 2004 Reader Survey!
Partners in Care

Dr. William Johnson and Bethsheba Johnson continue the vision of Dr. Sherry Luck

 

People with HIV/AIDS have unique problems that go beyond the medical aspects of the disease. The social stigma that is associated with HIV/AIDS frequently results in loss of emotional and physical support from family and friends. Even when this support exists, the enormous demands of the disease can create burdens beyond the patient’s and family’s ability to handle.

Sherry L. Luck, M.D. founded the Roseland Community Hospital HIV/AIDS clinic in 1994. As a board certified Internal Medicine Specialist, Dr. Luck had a vision of providing care for HIV-positive patients and their families in an underserved area of Chicago.

Dr. Luck realized early on that when a person is living with HIV or AIDS that the entire community is impacted. Her commitment to HIV/AIDS was a response to the dire need in the African American community. Prior to the establishment of the clinic, a comprehensive program to address the needs of people infected with and impacted by HIV did not exist on the far South Side of Chicago.

At the age of 44, Dr. Luck died in her sleep in May 1999. Through diligence and preservation, Dr. Luck’s vision was continued. The Luck Care Center was dedicated in honor of Dr. Luck’s memory and Dr. William Johnson and his wife Bethsheba Johnson continue her vision.

It was Dr. Luck who persuaded Bethsheba, a nurse practitioner, to join her in 1997. Although the work is all consuming and the hours long, Bethsheba energetically proclaims, “I can’t think of doing anything else.”

Dr. William A. Johnson, a board certified Internal Medicine Specialist, is now the Medical Director of the Luck Care Center, an appointment he has held for five years. He completed his residency at Rush Hospital in the HIV/AIDS unit during the early 1990s.

Providing a caring, professional staff makes it more likely that the client will keep appointments, improve adherence and reduce and eliminate high-risk behaviors.

Until March of 2003, the clinic was under the umbrella of Roseland Community Hospital. Today, Luck Care Center is under the not-for-profit umbrella of the Southside Health Association, of which Dr. Johnson serves as President.

The passion that Dr. Johnson and Bethsheba Johnson have for their patients and the community is immediately apparent. The clinic provides a place for individuals to come for HIV specialty care in their neighborhood. With so many institutionalized barriers to care, “this is a change for the better,” states Bethsheba.

Prior to the opening of the clinic, patients had to travel to other parts of the city and faced several unnecessary barriers to care, including the “South Side vs. West Side” division, inadequate transportation, and childcare problems. Or in other instances, patients received care via the public health clinics, which in Chicago fortunately are staffed by competent HIV physicians, however patients had to contend with the additional stigma of going to a public health clinic for care.

In the mid-1990s, Bethsheba remembers that so many of her patients would come into the hospital at “death’s door” with PCP or other AIDS-related opportunistic infections (OI). She is grateful that several of these same individuals are “working and productive” again. But still she is “surprised that so many people today still don’t know about treatment and come into care presenting an OI.”

Today the client base at Luck Care Center is approaching 200. While the majority of the patients are African American men who have sex with men, Bethsheba states they are seeing more African American women—younger, married and with children—who are being infected with HIV via unprotected heterosexual sex.

A history of mental health, substance abuse and illiteracy often compound treating the clients Dr. Johnson serves at Luck Care Center. Because of these multiple issues, Dr. Johnson believes clients have a more difficult time accessing care, understanding HIV disease, and adhering to antivirals. “Developing a treatment plan that encompasses the current and past life experience of the patient is even more important” in this regard states Dr. Johnson.

Providing a caring, professional staff dedicated to excellence in the community and engaging the client as a partner in the management of HIV disease makes it more likely that the client will keep appointments, improve adherence and reduce and eliminate high-risk behaviors.

Clinical Trials

Prior to joining Dr. Luck, Bethsheba worked for seven years at the Northwestern Memorial Hospital as a pulmonary clinical nurse, working primarily with clinical trials. “There has always been a disparity in gender and people of color in clinical trials,” she states. Dr. Johnson adds, “in the clinic I’ve observed the differences in how HIV disease progresses in people of color and women, as well as how these groups process antivirals and cope with their side effects.” Both agree that there is a need to recruit more people of color and women into clinical trials in order to gain a better perspective on disease management.

In this regard, both Dr. Johnson and Bethsheba Johnson have been working closely with Dr. Kimberly Smith, of Rush University Medical Centers and a lead researcher of the ACTG (AIDS Clinical Trials Group), to expand access and participation in clinical trials. The ultimate goal is to have Luck Care Center become a satellite office for the ACTG in Chicago. Dr. Johnson states that, “the education of the clients is key to success in recruitment.” Bethsheba and Dr. Smith have spent a great deal of time speaking with clients and service providers across the South Side of the city to increase awareness and encourage participation.

Several of their patients have clinical trial experience and were more than willing to share their knowledge.

Howard Spiller

Howard Spiller is a 39 year-old African American man who was diagnosed with HIV in 1986.

In 1996, he suffered a devastating stroke that has partially affected his mobility, but not his willpower. A few years ago following extensive rehabilitation and initiating HAART, Spiller entered a Procrit trial studying the impact of anemia on HIV-positive individuals.

The best part of the study, as Spiller remembers, was the level of care. “Every month I was having my labs done,” he recounts. “Having this information explained on a regular basis really informed me about my HIV and taught me to advocate for myself.”

The experience inspired Spiller to become involved with the Ryan White Care Council and the HIV Prevention Planning Group in Chicago. However before entering any clinical trial, Spiller suggests that “individuals interview physicians involved with trials, ask clarifying questions, find out the benefits and risks for your health and whether the results of the trial benefit others, especially African Americans living with HIV.”

One Women’s Story

Another patient of Dr. Johnson is a young African American mother of three small children, who asked that her name be withheld from the story. Myrna [not her actual name] was diagnosed with HIV nearly four years ago and lost her husband to AIDS in 2001. She has spent the last few years caring for her children, who are HIV negative, and learning as much as she can about this disease that causes AIDS. “I’m infected, but that doesn’t mean I’m going to die.”

She enrolled in a clinical trial combining Viracept and Combivir several years ago because as she states, “I wanted the best chance to survive and see my children grow up. So many people I encounter are not informed on how to live with this virus. We need to change how we live in order to survive.”

Myrna admits that she was a nervous wreck when she first entered care and the clinical trial. However, her hesitation has all subsided, replaced by a strong desire to share her experience and help others living with HIV. She volunteers in the clinic as a peer advocate. “God has restored my health,” she proclaims. “I feel as if I have a calling to help other women, like myself, who have struggled.” She credits much of her treatment success to the care she has received from her providers at Luck Care Center.

Challenges Ahead

While the expansion of clinical trials is paramount to the long term survivability of women and people of color living with HIV, the amount of administrative follow-up and paperwork is a huge barrier to recruitment and participation in trials for smaller clinics such as Luck Care Center.

Myrna admits that she was a nervous wreck when she first entered care and the clinical trial.

The center, like many HIV specialty centers across the U.S. not affiliated with a major research institution, is limited by available resources. “The process of case reporting and recruitment is time consuming” states Bethsheba. Dr. Johnson adds “it is important to have someone on staff dedicated to recruitment and paperwork,” in order for the clinical trial process to be successful at a smaller specialty center.

It is also important for the Center to be knowledgeable and understand its responsibility in the clinical trial process. “You need to know whether blood work and certain tests are covered by the trials. These can get to be expensive over time,” states Dr. Johnson. Luck Care Center has experienced its own growing pains in this regard, but is learning how to negotiate with companies sponsoring trials in order to ensure that administrative overhead and as many tests (e.g. PCR) as possible are covered.

Dr. Johnson and Bethsheba Johnson are true partners in care. Together they carry on Dr. Luck’s vision while seeking to guide the growth of the clinic in local, national and international arenas. While the work is daunting and there never seems to be enough funding, Dr. Johnson concludes that it is their “faith and belief in God that keeps us [he and his wife] and this clinic together.”

One-on-One with Gregory Braxton

Gregory Braxton, 48, is an AIDS treatment and clinical trial advocate. He is currently a member of the HIV Prevention Planning Group, a community-planning group working in collaboration with the HIV/AIDS/STD Division of the Chicago Department of Public Health to stem the rising tide of HIV and STD infections in the Chicago area.

He is living with AIDS and would be considered a salvage patient when it comes to his experience with antivirals. He was diagnosed with AIDS in 1994, with a T-cell count of 60.

Braxton has participated in multiple clinical trials, including Viracept, Kaletra and most recently the T-20 (Fuzeon) Phase III trial and is enrolled in the Phase II TMC 125 trial. “I got paid for a trial many years ago, but blew all the money on drugs and didn’t take the meds as I should. I lied to the doctor.”

Braxton, like many individuals with long-term addiction problems, “blew” his first, second, and third regimens because of a history of drug use. By the time he entered the T-20 study he “had no other choice.” Now he says, “I’ve learned the hard way how important adherence can be.” He remained on T-20 for about 6 to 8 months before stopping because it didn’t lower his viral load.

It was at a community update presented at TPAN on clinical data presented at the 2002 International AIDS Conference (Barcelona) that Braxton first heard about T-20. He then went and talked with his primary care physician about T-20 and expressed his interest in joining the trial. “With my substance abuse history, using needles to inject T-20 was not a problem for me,” Braxton jokes.

Earlier this year, he entered the Tibotec trial for the experimental protease inhibitor TMC 125. When he entered the trial his viral load was at 250,000 on a failing regimen. However within 2 months of adding TMC 125 to his regimen and (restarting) T-20 his viral load declined to 13,000.

Clinical trials vary greatly. Braxton cautions individuals considering joining a trial to review the study protocol carefully and if they can’t understand the “jargon” to make certain everything is explained carefully by the practitioner. “Listen and ask questions,” he says. His current trial is covering the cost of Braxton’s monthly doctor appointments and lab work to monitor his progress on TMC 125. However, it only covers the study drug (TMC 125), not all of the drugs in his current regimen. Braxton says he doesn’t feel like a guinea pig, because as he states, “I believe I’m receiving state-of-the-art care.” However, he cautions individuals to monitor themselves closely for side effects. “Being altruistic is great, but you have to look out for yourself.”

One-on-One with Paula Turner

Paula Turner is an outreach case manager at the AIDS Research Alliance Chicago (ARAC). She herself has participated in many clinical trials.

Turner recounts that she once got more than $2,500 for one study at Evanston Hospital, in 1995 or ‘96. “I spent two weeks in the hospital with an IV drip, with 69 other people. We played video games and ordered pizzas. We had a blood draw every four to six hours around the clock. They would wake us up. We went through a rigorous screening, and we got paid for that too. The drug didn’t even make it to first base.

“I was given the best of care. I did see other people get sick, but I never did. In that one study, I went in with about 275 T-cells and came out with 140 or 170. That scared the dickens out of me. That’s why I got on medications. They immediately went up, to more than 300. But I got an AIDS diagnosis when they dropped and it’s still there in my file.”

In her current job she helps to keep people engaged in the clinical trial process. “People lose interest in making appointments. A lot of people don’t like going to the doctor. But if we don’t get consistent data, the study might be a wash.”

Over the years, Turner has found that people enter trials for multiple reasons, but definitely not in the numbers she would like to see. Initially Turner herself would use a study to get labs results, “because I wanted to know my numbers,” she states. “With all the resources there are in Chicago, there’s not that many people accessing them, and I’ve never understood that. People in Africa wish they could get that.”

The majority of the people Turner encounters are encouraged by what they’re offered, “be it a coupon, a hundred dollars or 20 dollars. People are definitely not doing it for the good of humanity. I give them a food voucher or a bus or movie pass, something to let them know I’m sincere. I’m not paying them. I’m encouraging them. This is for you to do for you. I don’t want them to be reliant on seeing me coming and seeing dollar signs. I’m pretty good at getting my point across.”

However, it is very difficult engaging and keeping the clients she works with involved with the clinical trial process. “Mostly it’s the hardships people are experiencing that are holding them back. Housing is a major problem. Some lack refrigeration for meds or are hiding their medications from other people.” Others, she states, need some form of mental health care. “This was on the burner before HIV came on board. And now it’s compounded. The reasons are valid and the services are shallow.”

Outreach is also important. “The more people see something, the more their curiosity is raised. Most of the high-end doctors don’t get out to the community. Maybe the clinical trial people—community members and doctors—could do more to keep studies in people’s minds. They need to let people know these trials are available.” Turner believes, “All of them are half-stepping.

“They also need to get some good trials. We know this medicine is chemotherapy in a pill.”

In Turner’s opinion the key to surviving long term with HIV is attitude. “Attitude is everything. In the back of my mind, I was really hoping and praying that I was in something that was going to work.”

| Positively Aware | 2004 HIV Drug Guide | Positively Aware en español |

|Chicago Area HIV Services Directory | Publications Home |

| Publications | Client Services | MOCHA | Events | Helping TPAN |

| Contacts and Staff | About TPAN | Ask TPAN | Links | TPAN Home |